MDM4 and melanoma: Through analysis of 1015 primary and 358 metastatic melanomas, Taylor E Aronff et al. [23] found that amplifications of MDM4 are associated with higher rate of metastasis, poorer therapeutic efficacy of immunotherapy and lower overall survival in metastatic melanomas.